The effect of extended anti-TSLP therapy on the respiratory epithelium is the subject of ongoing extension trials in severe asthma, which will reveal whether normalizing the alarmin response can improve or prevent the structural changes associated with airway hyperresponsiveness, fixed airway obstruction, and mucous metaplasia. This evidence concerns the gene TSLP and asthma.